CN104003935A - 一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 - Google Patents
一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN104003935A CN104003935A CN201410208832.2A CN201410208832A CN104003935A CN 104003935 A CN104003935 A CN 104003935A CN 201410208832 A CN201410208832 A CN 201410208832A CN 104003935 A CN104003935 A CN 104003935A
- Authority
- CN
- China
- Prior art keywords
- yuan
- acetonitrile
- naphthalimide
- aroyl
- imide compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 66
- -1 fluoride ions Chemical class 0.000 claims abstract description 63
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 125000005605 benzo group Chemical group 0.000 claims abstract description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 11
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 9
- 238000010189 synthetic method Methods 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 claims description 6
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000005815 base catalysis Methods 0.000 claims description 3
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims description 3
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007255 decyanation reaction Methods 0.000 claims description 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- KRRBFUJMQBDDPR-UHFFFAOYSA-N tetrabutylazanium;cyanide Chemical compound N#[C-].CCCC[N+](CCCC)(CCCC)CCCC KRRBFUJMQBDDPR-UHFFFAOYSA-N 0.000 claims description 2
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 4
- 125000004799 bromophenyl group Chemical group 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 17
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 abstract description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract description 6
- 150000007962 benzene acetonitriles Chemical class 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 238000001308 synthesis method Methods 0.000 abstract description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract description 3
- 235000010290 biphenyl Nutrition 0.000 abstract description 3
- 239000004305 biphenyl Substances 0.000 abstract description 3
- 239000012046 mixed solvent Substances 0.000 abstract description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 239000000843 powder Substances 0.000 description 26
- 239000013078 crystal Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 16
- 150000001450 anions Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BMGGRMPPMMGODK-UHFFFAOYSA-N diazanium chloride fluoride Chemical compound [NH4+].[NH4+].[F-].[Cl-] BMGGRMPPMMGODK-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229940006477 nitrate ion Drugs 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N21/643—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" non-biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Plasma & Fusion (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开一种4-芳酰基-1,8-萘酰亚胺类化合物及合成方法和应用,所述4-芳酰基-1,8-萘酰亚胺类化合物的结构式如下:,其中R1为C1-C10直链或支链的烷基;R2为苯基、萘基、联苯基、取代苯基、5元或6元的杂芳基或苯并5元或6元杂芳基。其合成方法即以4溴-1,8-萘酰亚胺类化合物为原料,有机溶剂中通过碱催化剂催化与取代的苯乙腈或芳环乙腈发生反应,得4-芳基乙腈-1,8-萘酰亚胺类化合物,然后在氟离子或氰根离子作用下得4-芳酰基-1,8-萘酰亚胺类化合物。所得4-芳基乙腈-1,8-萘酰亚胺类化合物作为检测氟离子或氰根离子的颜色或荧光传感器,混合溶剂中识别氰根离子,具有高灵敏度和高选择性。
Description
技术领域
本发明主要应用于阴离子识别领域,特别是涉及到一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用。
背景技术
阴离子识别,特别是针对氟离子及氰根的识别,在生命,医药,环境等领域有着重要的应用。过量氟离子的摄入可导致牙齿、骨骼组织代谢疾病产生;饮用水中的氟离子超标也是重要的检测指标;同时,高毒CN离子的检测在环境及生物体系里有着重要应用。
颜色及荧光化学传感器可通过将分子识别的信息转换成易被感知的颜色信号或荧光信号,具有灵敏,快速及检测极限低等特点,可广泛应用在生物化学、细胞生物学和分析化学等相关领域。
萘酰亚胺类化合物是一类非常优良的荧光团,具有荧光强烈、色彩鲜艳以及热稳定性好等特性。目前报道的萘酰亚胺作为发色团而应用在阴离子识别领域比较多,然而大多数受体主要集中在4位溴与含NH或OH等基团发生取代反应,特别的是4位含脲基团或氨酰化等作为阴离子的作用位点。4-酰基或芳基乙腈基萘酰亚胺并未有较多的报道,而其相关的合成报道主要集中在4位芳基CH通过傅克酰基化反应得到,该方法存在反应条件苛刻且副反应较多,收率低等缺点。(EP. 2251687A1; Polymer 45 (2004) 6445;Polymer 41 (2000) 2367;Polymer Degradation and Stability 97 (2012) 1581;J. Org. Chem. 2010, 75, 2989;Macromolecules 2000, 33, 4310;J. Org. Chem. 1983,48,4097; J. Org. Chem. 2004, 69, 1364;J. Org. Chem. 2013, 78, 4974)。
发明内容
本发明的目的之一在于提供一种4-芳酰基-1,8-萘酰亚胺类化合物。
本发明的目的之二在于提供上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的合成方法。
本发明的目的之三在于提供一种上述4-芳酰基-1,8-萘酰亚胺类化合物的合成方法过程中所产生的中间产物4-芳基乙腈-1,8-萘酰亚胺类化合物,及该4-芳基乙腈-1,8-萘酰亚胺类化合物作为检测阴离子的颜色探针或荧光探针的应用,特别是在作为检测氟离子或氰根离子的颜色探针或荧光探针的应用。
本发明提供的技术方案
一种4-芳酰基-1,8-萘酰亚胺类化合物,其结构通式如下:
其中R1为R1为甲基、乙基、丙基、正丁基、正戊基、正己基、正庚基、正辛基、正壬基或正癸基等烷基;
R2为苯基、萘基、联苯基、取代苯基、5元或6元的杂芳环基或苯并5元或6元杂芳环基;其中所述5元或6元杂芳基的杂原子为N或/和O,杂原子个数为1或2;
其中,取代苯基为对氟苯基、邻氯苯基、邻溴苯基、对甲氧基苯基、间甲氧基苯基或间溴苯基;
5元杂芳基为呋喃基、吡咯基或咪唑基;
6元杂芳基为吡啶基或嘧啶基;
苯并5元杂芳基为苯并呋喃基、苯并咪唑基、BOC保护的吲哚基或吲哚基;
苯并6元杂芳基为苯并吡啶基或苯并嘧啶基。
上述4-芳酰基-1,8-萘酰亚胺类化合物的合成方法,其合成路线如下所示:
。
即以N-R1-4-溴-1,8萘酰亚胺为起始原料,在有机溶剂1中,通过碱催化,与取代的苯乙腈或芳环乙腈,按摩尔比1:1.1-1.8,在室温或回流温度下,反应时间4-10h,使4位溴与取代的苯乙腈或芳环乙腈中的亚甲基反应制备的4-芳基乙腈-1,8-萘酰亚胺类化合物;
进一步地,4-芳基乙腈-1,8-萘酰亚胺类化合物在有机溶剂2中经四丁基氟化铵作用制备的4-芳酰基-1,8-萘酰亚胺类化合物。
上述4-芳酰基-1,8-萘酰亚胺类化合物的合成方法,具体步骤如下:
(1)、以N-R1-4-溴-1,8萘酰亚胺为起始原料,在有机溶剂1中,通过碱催化,与取代的苯乙腈或芳环乙腈进行回流取代反应4-10h,所得的反应液柱层析分离处理得到4-芳基乙腈-1,8-萘酰亚胺类化合物;
所述的有机溶剂1为甲苯或四氢呋喃,其用量,按每克N-R1-4-溴-1,8萘酰亚胺原料,所用有机溶剂1的量为10-15毫升的比例计算;
所述碱催化剂为钠氢或甲醇钠;
上述所述的N-R1-4-溴-1,8萘酰亚胺与取代的苯乙腈或芳环乙腈按摩尔比1:1.1-1.8;
所述的碱催化剂的用量,按N-R1-4-溴-1,8萘酰亚胺:碱催化剂的摩尔比为1:1.2-1.8;
上述所得的N-R1-4-芳基乙腈-1,8-萘酰亚胺类化合物可用于对阴离子进行检测,即作为检测阴离子的颜色探针或荧光探针的应用。特别是作为检测氟离子或氰根离子的颜色探针或荧光探针;
(2)、步骤(1)所得的4-芳基乙腈-1,8-萘酰亚胺类化合物在有机溶剂2中经四丁基阴离子季铵盐催化剂作用下,室温下进行阴离子诱导分子内脱氢、脱氰基反应2-10h,所得的反应液经柱层析处理得到的4-芳酰基-1,8-萘酰亚胺类化合物;
所述的有机溶剂2为乙腈、乙醇或二甲基甲酰胺等,其用量,按每克N-R1-4-芳基乙腈-1,8-萘酰亚胺化合物原料,所用有机溶剂2的量为10-15毫升的比例计算;
所述的四丁基阴离子季铵盐催化剂为四丁基氟化铵或四丁基氰化铵,优选四丁基氟化铵,其用量,按N-R1-4-芳基乙腈-1,8-萘酰亚胺类化合物:四丁基阴离子季铵盐的摩尔比为1:1.2-1.5;
由于1,8-萘酰亚胺类化合物在染料及药物等领域广泛应用及芳酰基中羰基可有效地进行官能团的变换,上述所得的4-芳酰基-1,8-萘酰亚胺类化合物,可用于合成抗抑郁药、抗肿瘤药、抗躁动不安药物及复杂染料分子的中间体。
本发明的有益效果
本发明的一种4-芳酰基-1,8萘酰亚胺类化合物的合成方法,由于以4-溴-1,8萘酰亚胺及取代芳基乙腈为起始原料,该原料属工业易得原料,因此该合成方法具有生产成本低的特点,同时,该合成方法的合成路线简单、新颖,反应容易控制,收率高等特点。
进一步,本发明的4-芳酰基-1,8萘酰亚胺类化合物的合成方法过程中的中间产物4-芳基乙腈基-1,8萘酰亚胺类化合物具有识别氟离子或氰根离子的功能,特别是对氰根离子具有超高的灵敏性和选择性。可作为检测氟离子或氰根离子的颜色或荧光传感器,在混合溶剂中高效对氰根识别,表现出高灵敏度和高选择性,该类衍生物在生物化学,环境科学,医药化学中对阴离子识别具有重要的应用价值。
附图说明
图1、应用实施例1中,实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物分别与氰根离子,氟离子,醋酸根离子,磷酸二氢根离子,氯离子,溴离子,碘离子,硝酸根离子,四氟硼酸根离子及高氯酸根离子作用的乙腈溶液的紫外光谱分析图;
图2a、应用实施例2中,实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物与CN-离子连续滴定作用所得的4-芳基乙腈-1,8-萘酰亚胺类化合物的乙腈溶液的紫外吸收图谱;
图2b、应用实施例2所得的4-芳基乙腈-1,8-萘酰亚胺类化合物的乙腈溶液在波长610处吸光度随氰根离子浓度变化的紫外光谱图。
图3a、应用实施例2中,实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物与CN-离子连续滴定作用所得4-芳基乙腈-1,8-萘酰亚胺类化合物的乙腈溶液的荧光发射光谱图;
图3b、应用实施例3所得的4-芳基乙腈-1,8-萘酰亚胺类化合物的乙腈溶液在波长440处荧光强度随氰根离子浓度变化的荧光光谱图。
具体实施方式
下面通过具体的实施例并结合附图对本发明进一步阐述,但并不限制本发明。
实施例1
一种4-芳基乙腈-1,8-萘酰亚胺类化合物,其结构式如下所示:
其中R1为C4直链烷基;
R2为苯基。
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
在50ml的三口瓶中,加入20ml的无水甲苯及苯乙腈(0.40g,3.42mmol),0.20g的NaH固体,氮气置换三次,磁力搅拌一段时间,开始滴加N-丁基-4-溴-1,8萘酰亚胺(1.0g,3.02mmol)与10ml的无水甲苯溶液,滴加用时约30min,滴毕,室温搅拌一段时间,TLC点板追踪至反应完全;反应完毕,向反应液中加入10%的稀盐酸溶液,调反应液pH=1-2左右,用乙酸乙酯萃取溶液,有机相用饱和食盐水洗涤2次,无水硫酸钠干燥,减压除去溶剂,硅胶过柱,洗脱剂为PE:EA=20:1,收集纯品最终得淡黄色固体粉末0.80g,收率为72.1%。
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:
1H NMR (500 MHz, CDCl3),δ 8.56 (d, J = 6.5, 2H), 8.18 (d, J = 8.5Hz, 1H), 7.83 (d, J = 7.5Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.30 (m, 5H), 5.83 (s, 1H), 4.11 (t, J = 7.5 Hz, 2H), 1.63 (m, 2H), 1.37 (m, 2H), 0.91 (t, J = 7.5Hz, 3H);
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (125 MHz, CDCl3)δ 163.79, 163.51, 137.56, 134.19, 131.36, 130.80, 129.58, 129.12, 128.94, 128.88, 127.94, 127.84, 127.67, 123.75, 123.69, 118.61, 100.00, 40.38, 40.28, 30.18, 20.36, 13.81;
上述所得的淡黄色固体粉末通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:HRMS-ESI (m/z): [M + H]+ Calcd. for (C24H20N2O2), 369.16030,Found:369.16122.
通过上述所得的淡黄色固体粉末的核磁共振谱数据、高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色固体粉末为N-正丁基-4-苯乙腈基-1,8-萘酰亚胺。
实施例2
一种4-芳基乙腈-1,8-萘酰亚胺类化合物, 其结构式如下所示:
其中R1为正丁基;
R2为4-氟苯基。
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
在100ml的三口瓶中,加入25ml的无水甲苯及对氟苯乙腈(0.50g, 3.70mmol),0.25g的NaH固体,氮气置换三次,室温搅拌一段时间后,开始滴加N-丁基-4-溴-1,8萘酰亚胺(1.10g, 3.32mmol)与20ml的无水甲苯溶液,滴毕之后,开始加热一段时间,TLC点板追踪至反应完全;反应完毕,向反应液中加入10%的稀盐酸溶液,调反应液PH=1-2左右,用乙酸乙酯萃取溶液,有机相用饱和食盐水洗涤2次,无水硫酸钠干燥,减压除去溶剂,硅胶过柱,洗脱剂为PE:EA=25:1,收集纯品最终得淡黄色固体粉末0.90g,收率为70.3%. 熔点为132.9-134.8 ℃,。
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:1H NMR (500 MHz, CDCl3), δ 8.63 (m, 2H), 8.21 (d, J = 10.5 Hz, 1H), 7.91(d, J = 8.5 Hz, 1H), 7.77(m, 1H), 7.33 (m, 2H), 7.08 (m, 2H), 5.89 (s, 1H), 4.18 (t, J = 7.5 Hz, 2H), 1.72 (m, 2H), 1.44 (m, 2H), 0.98(t, J = 7.5Hz, 3H);
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (125 MHz, CDCl3) δ 163.93, 163.71, 163.42, 161.46, 137.17, 131.42, 130.78, 129.97, 129.48, 128.94, 128.70, 127.90, 123.78, 118.46, 116.67, 40.40, 39.59, 30.16, 20.37 13.84 ;
上述所得的淡黄色固体粉末通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:
HRMS-ESI (m/z): [M + H]+ Calcd. for (C24H20FN2O2), 387.15088, Found:387.15405.
通过上述所得的淡黄色固体粉末的核磁共振谱数据、高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色固体粉末物质为N-正丁基-4-(4-氟苯乙腈基)-1,8-萘酰亚胺。
上述仅以R2为4-氟苯基进行举例,本领域技术人员可以根据上述的实施例,通过调整相应的底物,得到R2为对氟苯基、邻氯苯基、邻溴苯基、对甲氧基苯基、间甲氧基苯基或间溴苯基的4-芳基乙腈-1,8-萘酰亚胺类化合物。
实施例3
一种4-芳基乙腈-1,8-萘酰亚胺类化合物,其结构式如下所示:
其中R1为正丁基;
R2为BOC保护的吲哚基。
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
室温下向50ml的三口烧瓶加入10ml无水甲苯和钠氢(0.36g,9.0mmol),氮气保护下加入吲哚-3-乙腈-N-甲基叔丁酯(0.29g,1.13mmol),0.5h后加入4-溴-1,8-萘酰亚胺(0.25g,0.76mmol),2h后点板跟踪反应结束。用饱和食盐水淬灭后加入50ml稀盐酸洗涤至酸性,溶液用乙酸乙酯萃取后硅胶柱分离,得到黄色固体粉末0.25g, 产率63%。
上述所得的黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:
1H NMR (400 MHz, CDCl3) δ 8.67(d, J = 6.4 Hz, 1H), 8.60(d, J = 7.2 Hz, 1H), 8.40(d, J = 8.4Hz, 1H), 8.16(d, J = 8.4Hz, 1H), 7.91(d, J = 7.6Hz, 1H), 7.82(t, J = 7.6Hz, 1H), 7.55(s, 1H), 7.39-7.33(m,2H), 7.21(t, J = 7.6Hz, 1H), 6.06(s, 1H), 4.19(t, J = 7.2Hz, 2H), 1.75-1.69 (m, 2H), 1.66(s, 9H), 1.48-1.43(m, 2H), 0.98(t, J = 7.2Hz, 3H).
上述所得的黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (100MHz DMSO- d6 ) δ 14.10, 20.21, 28.00, 30.00, 31.18, 39.86, 85.06, 114.93, 115.62, 119.32, 119.83, 123.33, 123.43, 123.54, 125.70, 127.62, 127.83, 128.83, 128.54, 128.96, 130.15, 130.97, 131.29, 135.43, 137.30, 149.14, 163.29, 163.54;
上述所得的黄色固体粉末通过红外光谱仪器(NICOLET 6700 FT-IR)进行测定,数据如下所示:
IR (KBr, cm-1) 2960, 2930, 2873, 2249 (-C≡N), 1780, 1736, 1659, 1595, 1449, 1388, 1355, 1308, 1254, 1155, 1088, 1021, 963, 864, 840, 784, 751;
上述所得的黄色固体粉末通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:
HMRS-ESI (m/z): [M+H]+ (calcd for C31H29N3O4) 508.22363; Found 508.22769.
通过上述所得的黄色固体粉末的核磁共振谱数据、红外光谱及高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色固体粉末为N-正丁基-4-(-3-氰乙基-吲哚叔丁脂基)-1,8-萘酰亚胺。
上述仅以R2为BOC保护的吲哚基进行举例,本领域技术人员可以根据上述的实施例,通过调整相应的底物,得到R2为联苯、萘环、苯并5元杂环或苯并6元杂环的4-芳基乙腈-1,8-萘酰亚胺类化合物。
实施例4
一种4-芳酰基-1,8-萘酰亚胺类化合物, 其结构式如下所示:
其中R1为正丁基;
R2为苯基。
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
在50ml的单口瓶中加入N-正丁基-4-苯乙腈基-1,8-萘酰亚胺(0.10g,0.27mmol),并加入20ml的乙腈,及正四丁基氟化铵(0.15g,0.47mmol),磁力搅拌下室温反应4-6h左右,反应完全后,减压蒸去溶剂,硅胶柱层析分离,洗脱剂为PE:EA=25:1,得淡黄色晶体0.092g,收率为94.8%。
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:
1H NMR (500 MHz, CDCl3), δ 8.58 (d, J = 7.5, 2H), 8.26 (d, J = 8.0 Hz, 1H), 7.78(d, J = 7.0 Hz, 2H), 7.73 (d, J =7.0Hz, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.59 (3, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 2H), 4.14(t, J = 7.5 Hz, 2H), 1.67 (m, 2H), 1.39 (m, 2H), 0.92 (t, J = 7.5Hz, 3H);
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (125 MHz, CDCl3) δ 196.32 , 163.92, 163.61, 141,88, 137.13, 134.14, 131.80, 131.64, 130.41, 129.73, 128.81, 128.53, 127.95, 127.35, 124.53, 123.01, 40.43, 30.20, 20.38, 13.83 ;
上述所得的淡黄色晶体通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:
HRMS-ESI (m/z): [M + H]+ Calcd. for (C23H19NO3), 358.14432, Found:358.14605.
通过上述所得的淡黄色晶体的核磁共振谱数据、高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色晶体为N-正丁基-4-苯酰基-1,8-萘酰亚胺类化合物。
实施例5
一种4-芳酰基-1,8-萘酰亚胺类化合物,其结构式如下所示:
其中R1为正丁基;
R2为4-氟苯基。
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
50ml的单口瓶中加入N-正丁基-4-(4-氟苯乙腈基)-1,8-萘酰亚胺(0.1g, 0.26mmol),并加入20ml的乙腈,及正四丁基氟化铵(0.15g,0.47mmol),磁力搅拌下室温反应4-6h左右,反应完全后,减压蒸去溶剂,硅胶柱层析分离,洗脱剂为PE:EA=30:1,得淡黄色晶体0.09g,收率为92.7%. 熔点为128.9-131.6 ℃。
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:
1H NMR (500 MHz, CDCl3),δ 8.66 (m, 2H), 8.31(dd, J = 7.5 ,1.0 Hz,1H), 7.90(m, 2H), 7.78 (m, 2H), 7.18 (m, 2H), 5.89 (s, 1H), 4.18 (t, J = 7.5 Hz, 2H), 1.74 (m, 2H), 1.47 (m, 2H), 1.00(t, J = 7.5Hz, 3H);
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (125 MHz, CDCl3) δ 194.72, 167.64, 165.08, 163.84, 163.53, 141.52, 133.48, 133.10, 131.68, 129.72, 129.26, 128.51, 128,04, 127.16, 124.60, 123.00, 116.12, 40.45, 30.19, 20.39, 13.86 ;
上述所得的淡黄色晶体通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:
HRMS-ESI (m/z): [M + H]+ Calcd. for (C23H19FNO3), 376.13490, Found:376.13860.
通过上述所得的淡黄色晶体的核磁共振谱数据、高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色晶体为N-正丁基-4-(4-氟苯酰基)-1,8-萘酰亚胺。
上述仅以R2为4-氟苯基进行举例,本领域技术人员可以根据上述的实施例,通过调整相应的底物,得到R2为对氟苯基、邻氯苯基、邻溴苯基、对甲氧基苯基、间甲氧基苯基或间溴苯基的4-芳酰基-1,8-萘酰亚胺类化合物。
实施例6
一种4-芳酰基-1,8-萘酰亚胺类化合物,其结构式如下所示:
其中R1为正丁基;
R2为BOC保护吲哚基。
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
上述的一种4-芳酰基-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
室温下向50ml的三口烧瓶内加入30ml二氯甲烷,N-正丁基-4-(-3-氰乙基-吲哚叔丁脂基)-1,8-萘酰亚胺(0.60g, 1.20mmol)和四正丁基氟化铵 (3.00g, 11.50mmol),0.5h后点板跟踪反应结束,水洗3次,干燥后硅胶柱分离,得到淡黄色晶体0.50g,产率85%。
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定,数据如下所示:
1H NMR (400 MHz, CDCl3) δ 8.69-8.65(m, 2H), 8.50-8.47(m, 2H), 8.17(m, 1H), 7.95(d, J = 7.6Hz, 1H), 7.84(s, 1H), 7.78(dd, J 1 = 7.2Hz, J 2 = 8.4Hz, 1H), 7.50-7.44(m, 2H), 4.16(t, J = 7.2Hz, 2H), 1.80-1.72(m, 2H), 1.64(s, 9H), 1.53-1.43(m, 2H), 1.02(t, J = 7.2Hz, 3H).
上述所得的淡黄色晶体通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定,数据如下所示:
13C NMR (100MHz CDCl3) δ 13.87, 20.40, 28.02, 29.70, 40.40, 86.02, 115.21, 120.65, 122.69, 122.88, 124.34, 124.88, 126.17, 126.53, 127.50, 127.87, 128.59, 129.11, 129.87, 131.62, 131.85, 135.60, 135.76, 142.73, 148.79, 163.62, 163.90, 190.96.
上述所得的淡黄色晶体通过红外光谱仪器(NICOLET 6700 FT-IR)进行测定,数据如下所示:
IR (KBr, cm-1) 2958, 2931, 2871, 1742, 1702, 1662, 1639, 1592, 1537, 1480, 1355, 1277, 1250, 1232, 1187, 1151, 1098, 1082, 1018, 935, 860, 847, 834, 779, 751, 695;
上述所得的淡黄色晶体通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定,数据如下所示:
HRMS-ESI(m/z):[M+H]+ (Calcd.for C30H28N2O5) 497.20765;Found 497.21371.
通过上述所得的淡黄色晶体的核磁共振谱数据、红外光谱及高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色晶体为N-正丁基-4-(叔丁脂基吲哚-3-酰基)-1,8-萘酰亚胺。
上述仅以R2为BOC保护吲哚基进行举例,本领域技术人员可以根据上述的实施例,通过调整相应的底物,得到R2为苯并呋喃、苯并吡咯、苯并吡啶或苯并嘧啶的4-芳酰基-1,8-萘酰亚胺类化合物。
实施例7
一种4-芳基乙腈-1,8-萘酰亚胺类化合物, 其结构式如下所示:
其中R1为正丁基;
R2为吲哚基。
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,其合成过程的反应式如下所示:
;
上述的一种4-芳基乙腈-1,8-萘酰亚胺类化合物的制备方法,具体步骤如下:
室温下向50ml的三口烧瓶内加入10ml二氯甲烷,5ml三氟乙酸和N-正丁基-4-(-3-氰乙基-吲哚叔丁脂基)-1,8-萘酰亚胺(1.0g, 1.97mmol),1.0h后点板跟踪反应结束,用30ml二氯甲烷稀释后水洗3次,干燥后硅胶柱分离,得到淡黄色固体粉末0.64g,产率80%。
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行氢谱测定的数据如下所示:
1H NMR (500 MHz, DMSO- d6 ) δ 11.32(s, 1H), 8.68(d, J = 8.5Hz, 1H), 8.58(d, J = 7.5Hz, 1H), 8.50(d, J = 7Hz, 1H), 8.13(d, J = 7.5Hz, 1H), 7.91(t, J = 7.5Hz, 1H), 7.55(d, J = 8.0Hz, 1H), 7.41(d, J = 8.5Hz, 1H), 7.34(d, J=2.0Hz, 1H), 7.13(t, J = 7.5Hz, 1H), 7.02(t, J = 7.5Hz, 1H), 6.95(s, 1H), 4.04(t, J = 7.5Hz, 2H), 1.64-1.58(m, 2H), 1.38-1.31(m, 2H), 0.92(t, J = 7.5Hz, 3H).
上述所得的淡黄色固体粉末通过核磁共振仪器(Bruker AVANCE III 500 MHz)进行碳谱测定的数据如下所示:13C NMR (100MHz DMSO- d6 ) δ 14.14, 20.22, 30.04, 31.80, 39.95, 108.81, 112.56, 118.75, 119.89, 120.30, 122.37, 122.90, 123.31, 125.37, 125.43, 127.14, 128.02, 128.57, 128.94, 130.53, 131.09, 131.18, 136.93, 139.01, 163.41, 163.65;
上述所得的淡黄色固体粉末通过红外光谱仪器(NICOLET 6700 FT-IR)进行测定,的数据如下所示:
IR (KBr) 3351 (-N-H), 2957, 2930, 2871, 2243 (-C≡N), 1701, 1655, 1617, 1592, 1458, 1389, 1352, 1270, 1232, 1190, 1085, 948, 868, 780, 743;
上述所得的淡黄色固体粉末通过高分辨质谱仪器(solanX 70 FT-MS)进行质谱测定的数据如下所示:HMRS-ESI (m/z):[M+H]+ (calcd for C26H21N3O2) 408.17120; Found 408.17481.
通过上述所得的淡黄色固体粉末的核磁共振谱数据、红外光谱及高分辨质谱方面的数据综合分析,结果表明,上述所得的淡黄色固体粉末物质为N-正丁基-4-(-3-氰乙基吲哚)-1,8-萘酰亚胺。
上述仅以R2为吲哚基进行举例,本领域技术人员可以根据上述的实施例,通过调整相应的底物,得到R2为吡咯的4-芳基乙腈-1,8-萘酰亚胺类化合物。
应用实施例1
称取4.7mg的实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物放入10毫升容量瓶中,用乙腈溶液定容,配置成1.154mmol/L的溶液。然后准确量取10份每份体积866uL的上述溶液稀释到50毫升,分别加入氰根离子,氟离子,醋酸根离子,磷酸二氢根离子,氯离子,溴离子,碘离子,硝酸根离子,四氟硼酸根离子,高氯酸根离子(2.1当量,阴离子当量:受体当量),定容至3毫升,配置成10份受体4-芳基乙腈-1,8-萘酰亚胺类化合物20uM与阴离子浓度42uM的乙腈溶液。
将上述配置的溶液静置1-2min后,通过肉眼观察,加入氰根离子的4-芳基乙腈-1,8-萘酰亚胺类化合物乙腈溶液有显著蓝色变化,其他阴离子变化很小或者没有变化,由此表明4-芳基乙腈-1,8-萘酰亚胺类化合物对氰根离子的选择性极高;
将上述所得的含氰根离子和氟根离子的4-芳基乙腈-1,8-萘酰亚胺类化合物乙腈溶液,通过紫外分光光度计分别测定其紫外光谱,吸收值,其紫外分析图如图1所示,从图1中可以看出,在氰根离子和氟离子作用下,4-芳基乙腈-1,8-萘酰亚胺类化合物溶液的吸收强度在610nm波长处出现新的吸收峰并伴随着溶液的蓝色产生(肉眼检测),其他阴离子几乎没有变化或者变化很小(很难通过肉眼检测到颜色变化),由此表明了4-芳基乙腈-1,8-萘酰亚胺类化合物可以肉眼高度选择性识别氰根离子和氟根离子,因此,由此4-芳基乙腈-1,8-萘酰亚胺类化合物可作为高选择性的氰根或氟离子探针。
应用实施例2
将实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物配制成20μM的乙腈溶液,同时每次滴加15μL的浓度为5000μM的氰根乙腈溶液,每次滴加完后分别通过紫外分光光度计记录所得的紫外吸收谱图,将多次滴加的图谱叠加即得到图2a、图2b;
从图2a中可以看出,随着氰根离子的加入,在610nm波长处有新的吸收峰,并且吸收强度持续增强,这表明4-芳基乙腈-1,8-萘酰亚胺类化合物分子与氰根阴离子发生了氢键作用,生成了复合物;
从图2b中可以看出,随着氰根离子浓度逐渐增加,吸收强度逐渐呈S型,并且当氰根离子浓度达到60μM时,溶液颜色达到饱和而不再变化;由此表明了氰根离子与4-芳基乙腈-1,8-萘酰亚胺类化合物生成了稳定的复合物。
应用实施例3
将实施例7所得的4-芳基乙腈-1,8-萘酰亚胺类化合物配制成20μM的乙腈溶液,同时每次滴加50μL的浓度为5000μM的氰根乙腈溶液,每次滴加完后分别通过荧光分光光度计记录所得的紫外吸收谱图,将多次滴加的图谱叠加即得到图3a、图3b;
从图3a中可以看出,随着氰根离子的加入,荧光强度在波长440处明显逐渐增强,由此表明了氰根与4-芳基乙腈-1,8-萘酰亚胺类化合物发生作用阻断电子转移进而产生荧光;
从图3b中可以看出,随着氰根离子达到24当量时,该4-芳基乙腈-1,8-萘酰亚胺类化合物的荧光强度不再变化,说明4-芳基乙腈-1,8-萘酰亚胺类化合物与氰根离子作用达到饱和。
综上所述,本发明提供了一种制备4-芳酰基-1,8-萘酰亚胺类化合物的简便合成方法,特别是合成过程中的中间产物4-芳基乙腈-1,8-萘酰亚胺化合物可作为氰根离子或氟离子的高选择的检测探针,特别地,该类探针能给出4-芳基乙腈-1,8-萘酰亚胺类化合物溶液从无色到蓝色的裸眼检测,同时给出明显的荧光增强“关-开”信号,因此,该4-芳基乙腈-1,8-萘酰亚胺类化合物可作为检测氟离子或氰根离子的检测试剂进而取得实际应用。
以上所述内容仅为本发明构思下的基本说明,而依据本发明的技术方案所作的任何等效变换,均应属于本发明的保护范围。
Claims (10)
1.一种4-芳酰基-1,8-萘酰亚胺类化合物,其特征在于所述的4-芳酰基-1,8-萘酰亚胺类化合物的结构式如下所示:
其中R1为C1-C10直链或支链的烷基;
R2为苯基、萘基、联苯基、取代苯基、5元或6元的杂芳基或苯并5元或6元杂芳基;所述5元或6元杂芳基的杂原子为N或/和O,杂原子个数为1或2。
2.如权利要求1所述的4-芳酰基-1,8-萘酰亚胺类化合物,其特征在于:
其中R1为甲基、乙基、丙基、正丁基、正戊基、正己基、正庚基、正辛基、正壬基或正癸基;
R2中的取代苯基为对氟苯基、邻氯苯基、邻溴苯基、对甲氧基苯基、间甲氧基苯基或间溴苯基;
5元杂芳基为呋喃基、吡咯基或咪唑基;
6元杂芳基为吡啶基或嘧啶基;
苯并5元杂芳基为苯并呋喃基、苯并咪唑基、BOC保护吲哚基或吲哚基;
苯并6元杂芳基为苯并吡啶基或苯并嘧啶基。
3.如权利要求2所述的4-芳酰基-1,8-萘酰亚胺类化合物,其特征在于,其中R1为正丁基;R2为苯基、4-氟苯基、BOC保护吲哚基或吲哚基。
4.如权利要求1-3中任一所述的4-芳酰基-1,8-萘酰亚胺类化合物的合成方法,其特征在于包括如下步骤:
(1)、以N-R1-4-溴-1,8萘酰亚胺为起始原料,在有机溶剂1中,通过碱催化,与取代的苯乙腈或芳环乙腈进行回流取代反应4-10h,所得的反应液柱层析分离处理得到4-芳基乙腈-1,8-萘酰亚胺类化合物;
所述的有机溶剂1为甲苯或四氢呋喃;其用量,按每克N-R1-4-溴-1,8萘酰亚胺原料,所用有机溶剂1为10-15毫升的比例计算;
所述碱催化剂为钠氢或甲醇钠;其用量,按N-R1-4-溴-1,8萘酰亚胺:碱催化剂的摩尔比为1:1.2-1.8;
上述所述的N-R1-4-溴-1,8萘酰亚胺与取代的苯乙腈或芳环乙腈按摩尔比1:1.1-1.8;
(2)、步骤(1)所得的4-芳基乙腈-1,8-萘酰亚胺类化合物在有机溶剂2中经四丁基阴离子季铵盐催化剂作用下,室温下进行阴离子诱导分子内脱氢、脱氰基反应2-10h,所得的反应液经柱层析处理得到的4-芳酰基-1,8-萘酰亚胺类化合物;
所述有机溶剂2为乙腈、乙醇或二甲基甲酰胺,其用量,按每克N-R1-4-芳基乙腈-1,8-萘酰亚胺化合物原料,所用有机溶剂2为10-15毫升的比例计算;
所述的四丁基阴离子季铵盐,其用量,按N-R1-4-芳基乙腈-1,8-萘酰亚胺类化合物:四丁基阴离子季铵盐的摩尔比为1:1.2-1.5。
5.如权利要求4所述的4-芳酰基-1,8-萘酰亚胺类化合物的合成方法,其特征在于步骤(2)中的所用的四丁基阴离子季铵盐催化剂为四丁基氟化铵或四丁基氰化铵。
6.如权利要求4所述的合成方法的步骤(1)所得的一种4-芳基乙腈-1,8-萘酰亚胺类化合物,其特征在于其结构式如下所示:
;
其中R1为C1-C10直链或支链的烷基;
R2为苯基、萘基、联苯基、取代苯基、5元或6元的杂芳基或苯并5元或6元杂芳基;所述5元或6元杂芳基的杂原子为N或/和O,杂原子个数为1或2。
7.如权利要求6所述的4-芳基乙腈-1,8-萘酰亚胺类化合物,其特征在于,其中R1为甲基、乙基、丙基、正丁基、正戊基、正己基、正庚基、正辛基、正壬基或正癸基;
R2中的取代苯基为对氟苯基、邻氯苯基、邻溴苯基、对甲氧基苯基、间甲氧基苯基或间溴苯基;
5元杂芳基为呋喃基、吡咯基或咪唑基;
6元杂芳基为吡啶基或嘧啶基;
苯并5元杂芳基为苯并呋喃基、苯并咪唑基、BOC保护吲哚基或吲哚基;
苯并6元杂芳基为苯并吡啶基或苯并嘧啶基。
8.如权利要求6所述的4-芳基乙腈-1,8-萘酰亚胺类化合物,其特征在于,其中R1为正丁基;R2为苯基、4-氟苯基、BOC保护吲哚基或吲哚基。
9.如权利要求6所述的4-芳基乙腈-1,8-萘酰亚胺类化合物作为检测阴离子的颜色探针或荧光探针的应用。
10.如权利要求6所述的4-芳基乙腈-1,8-萘酰亚胺类化合物作为检测氟离子或氰根离子的颜色探针或荧光探针的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410208832.2A CN104003935A (zh) | 2014-05-16 | 2014-05-16 | 一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410208832.2A CN104003935A (zh) | 2014-05-16 | 2014-05-16 | 一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104003935A true CN104003935A (zh) | 2014-08-27 |
Family
ID=51364870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410208832.2A Pending CN104003935A (zh) | 2014-05-16 | 2014-05-16 | 一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104003935A (zh) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478855A (zh) * | 2014-12-09 | 2015-04-01 | 上海应用技术学院 | 3-氨基-4-((e)-吡啶-2(1氢)-烯乙腈基)-1,8-萘酰亚胺类衍生物 |
| CN105985291A (zh) * | 2015-11-10 | 2016-10-05 | 济南大学 | 一种快速高选择性分析氟离子的比色荧光探针 |
| CN106518763A (zh) * | 2016-11-03 | 2017-03-22 | 商丘师范学院 | 一种高选择性比率式检测氰根离子的荧光探针及其合成方法与应用 |
| CN107118155A (zh) * | 2017-05-22 | 2017-09-01 | 上海应用技术大学 | 一种4‑芳乙醇基‑1,8‑萘酰亚胺类化合物及其制备方法和应用 |
| CN108640874A (zh) * | 2018-04-03 | 2018-10-12 | 深圳大学 | 一种分子探针及其制备方法与应用 |
| CN109053572A (zh) * | 2018-09-27 | 2018-12-21 | 上海应用技术大学 | 4-三氟甲基-6-溴-2-取代乙腈-1,8-萘酰亚胺类化合物及其制备方法和应用 |
| CN111019646A (zh) * | 2019-12-23 | 2020-04-17 | 湖北工业大学 | 一种萘酰亚胺并吡咯并[2,1-b][1,3]苯并噁嗪衍生物CN-探针的制备与应用 |
| CN111518128A (zh) * | 2020-04-01 | 2020-08-11 | 上海应用技术大学 | 一种检测氟离子的荧光探针及其制备方法和应用 |
| CN114044767A (zh) * | 2021-10-28 | 2022-02-15 | 上海应用技术大学 | 一种检测氰根离子的荧光探针及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| CN101304973A (zh) * | 2005-09-15 | 2008-11-12 | 佩因赛普托药物公司 | 调节神经营养蛋白介导的活性的方法 |
| US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
-
2014
- 2014-05-16 CN CN201410208832.2A patent/CN104003935A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| CN101304973A (zh) * | 2005-09-15 | 2008-11-12 | 佩因赛普托药物公司 | 调节神经营养蛋白介导的活性的方法 |
| US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
Non-Patent Citations (4)
| Title |
|---|
| FRANCIS, E. M.,等,: "Derivatives of Naphthalomethylimide", 《JOURNAL OF THE CHEMICAL SOCIETY》, 31 December 1935 (1935-12-31), pages 496 - 499 * |
| JINJU CHEN,等: "A novel chemodosimeter for fluoride ions based on deprotonation of the C–H group followed by an autoxidative decyanation process", 《CHEM. COMMUN.》, vol. 49, no. 92, 1 October 2013 (2013-10-01), pages 10814 - 10816 * |
| PETERS, A. T.,等: "Derivatives of 3",2-acenaphthoylbenzoic acid", 《JOURNAL OF THE SOCIETY OF DYERS AND COLOURISTS》, vol. 59, 31 December 1943 (1943-12-31), pages 52 - 54 * |
| 杜葩: "一种新型荧光探针的光谱性能", 《上海应用技术学院学报》, vol. 5, no. 4, 31 December 2005 (2005-12-31), pages 255 - 258 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478855A (zh) * | 2014-12-09 | 2015-04-01 | 上海应用技术学院 | 3-氨基-4-((e)-吡啶-2(1氢)-烯乙腈基)-1,8-萘酰亚胺类衍生物 |
| CN105985291A (zh) * | 2015-11-10 | 2016-10-05 | 济南大学 | 一种快速高选择性分析氟离子的比色荧光探针 |
| CN106518763B (zh) * | 2016-11-03 | 2019-04-09 | 商丘师范学院 | 一种选择性比率式检测氰根离子的荧光探针及其合成方法与应用 |
| CN106518763A (zh) * | 2016-11-03 | 2017-03-22 | 商丘师范学院 | 一种高选择性比率式检测氰根离子的荧光探针及其合成方法与应用 |
| CN107118155A (zh) * | 2017-05-22 | 2017-09-01 | 上海应用技术大学 | 一种4‑芳乙醇基‑1,8‑萘酰亚胺类化合物及其制备方法和应用 |
| CN108640874A (zh) * | 2018-04-03 | 2018-10-12 | 深圳大学 | 一种分子探针及其制备方法与应用 |
| CN109053572A (zh) * | 2018-09-27 | 2018-12-21 | 上海应用技术大学 | 4-三氟甲基-6-溴-2-取代乙腈-1,8-萘酰亚胺类化合物及其制备方法和应用 |
| CN109053572B (zh) * | 2018-09-27 | 2022-02-11 | 上海应用技术大学 | 4-三氟甲基-6-溴-2-取代乙腈-1,8-萘酰亚胺类化合物及其制备方法和应用 |
| CN111019646A (zh) * | 2019-12-23 | 2020-04-17 | 湖北工业大学 | 一种萘酰亚胺并吡咯并[2,1-b][1,3]苯并噁嗪衍生物CN-探针的制备与应用 |
| CN111019646B (zh) * | 2019-12-23 | 2023-03-31 | 湖北工业大学 | 一种萘酰亚胺并吡咯并[2,1-b][1,3]苯并噁嗪衍生物CN-探针的制备与应用 |
| CN111518128A (zh) * | 2020-04-01 | 2020-08-11 | 上海应用技术大学 | 一种检测氟离子的荧光探针及其制备方法和应用 |
| CN111518128B (zh) * | 2020-04-01 | 2022-08-23 | 上海应用技术大学 | 一种检测氟离子的荧光探针及其制备方法和应用 |
| CN114044767A (zh) * | 2021-10-28 | 2022-02-15 | 上海应用技术大学 | 一种检测氰根离子的荧光探针及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104003935A (zh) | 一种4-芳酰基-1,8-萘酰亚胺类化合物及其制备方法和应用 | |
| Reena et al. | Synthesis and anion binding studies of azo-Schiff bases: Selective colorimetric fluoride and acetate ion sensors | |
| Liu et al. | Fluorescent sensors for amino acid anions based on calix [4] arenes bearing two dansyl groups | |
| Bentley et al. | Chirality imprinting and direct asymmetric reaction screening using a stereodynamic Brønsted/Lewis acid receptor | |
| CN104478855B (zh) | 3‑氨基‑4‑((e)‑吡啶‑2(1氢)‑烯乙腈基)‑1,8‑萘酰亚胺类衍生物 | |
| Cao et al. | 4-Nitrobenzene thiourea self-assembly system and its transformation upon addition of Hg2+ ion: Applications as sensor to fluoride ion | |
| Zhao et al. | A near-IR fluorescent probe for enantioselective recognition of amino acids in aqueous solution | |
| CN102942541B (zh) | 一种受体化合物及其合成和在比色检测氟离子中的应用 | |
| Gong et al. | A novel amidepyridinium-based tripodal fluorescent chemosensor for phosphate ion via binding-induced excimer formation | |
| Cui et al. | A colorimetric chemosensor for pyrophosphate based on mono-pyrenylurea in aqueous media | |
| CN113372276B (zh) | 吲唑类衍生物及其应用 | |
| Teimouri | Serendipitous stereoselective synthesis of brand-new fluorescent dyes:(1Z)-3-(alkylimino)-1-[(chromone-3-yl) methylene]-1, 3-dihydro-9H-furo [3, 4-b] chromen-9-one-type fluorophores with blue fluorescence emission properties | |
| CN103937487B (zh) | 一种磷光氟离子探针及其制备和应用 | |
| Zhang et al. | A photo-stable fluorescent chiral thiourea probe for enantioselective discrimination of chiral guests | |
| Tyszka et al. | Late-Stage Functionalization of (R)-BINOL-Based Diazacoronands and Their Chiral Recognition of α-Phenylethylamine Hydrochlorides | |
| CN107118155A (zh) | 一种4‑芳乙醇基‑1,8‑萘酰亚胺类化合物及其制备方法和应用 | |
| Zhu et al. | A cis tetraphenylethene-based Zn complex as probe for selective detection of triphosphate | |
| CN115806506A (zh) | 一种修饰的八氢联二萘酚类化合物及其制备方法、应用 | |
| CN103275022B (zh) | 1-苄基-1,2,3-三氮唑类化合物及其制备方法和应用 | |
| Madry et al. | Point-to-axial chirality transmission: A highly sensitive triaryl chirality probe for stereochemical assignments of amines | |
| CN118908958B (zh) | 一种cdk4/6小分子荧光探针及其制备方法和应用 | |
| Li et al. | Synthesis, binding ability, and cell cytotoxicity of fluorescent probes for L‐arginine detection based on naphthalene derivatives: Experiment and theory | |
| CN104109153A (zh) | 一种化合物及其应用于单胺氧化酶活性的荧光检测方法 | |
| CN104151248B (zh) | 双咪唑丹磺酰衍生物阳离子型荧光探针及其合成方法和应用 | |
| CN106478646B (zh) | 一种罗丹明-胍基苯并咪唑功能化的光敏探针及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140827 |